Can Vascular Dementia Be Reversed or Slowed?

Vascular dementia caused by established brain damage from strokes or chronic small vessel disease cannot be fully reversed, but the cognitive decline it causes can often be slowed and, in some cases, partially improved. Unlike Alzheimer’s disease, where the underlying neurodegenerative process is largely independent of controllable factors, vascular dementia is driven by problems in blood supply to the brain, and many of those problems are tied to treatable conditions like high blood pressure, diabetes, and heart disease. That distinction gives patients and families more levers to pull than the diagnosis might initially suggest.

Why the Damage Is Hard to Undo

Vascular dementia results from reduced or blocked blood flow to the brain, which starves neurons of oxygen and nutrients. This can happen suddenly, as in a large stroke, or gradually through damage to tiny blood vessels deep in the brain. In the early stages of small vessel disease, the functional units where neurons, blood vessel lining cells, and supporting cells work together start to break down. That breakdown triggers a cascade: the blood-brain barrier begins to leak, the brain’s ability to regulate its own blood flow weakens, inflammation ramps up, and vessel walls thicken and narrow.¹ Once brain tissue has been destroyed by a stroke or prolonged oxygen deprivation, that tissue does not regenerate. The neurons are gone.

But “the neurons are gone” is not the whole story. The brain has some ability to compensate for lost territory by rerouting functions through surviving networks, a process called neuroplasticity. And a significant portion of cognitive impairment in vascular dementia comes not from dead tissue but from tissue that is struggling: areas with reduced blood flow, ongoing inflammation, or swelling that can potentially improve if the underlying vascular problems are addressed. The goal of treatment is to protect the brain tissue that remains and, where possible, restore function in areas that are impaired but not destroyed.

Blood Pressure Control Is the Strongest Lever

High blood pressure is the single most influential modifiable risk factor for vascular dementia, and treating it is the intervention with the longest track record. Research dating back decades found that in patients with multi-infarct dementia (an older term for vascular dementia caused by multiple small strokes), bringing systolic blood pressure into the range of roughly 135 to 150 mm Hg was associated with improved cognition. Interestingly, patients whose blood pressure was pushed too low actually got worse, suggesting the damaged brain needs adequate pressure to maintain blood flow through narrowed vessels.²

More recent work supports the idea that blood pressure management protects the brain’s wiring. A large substudy of the SPRINT trial found that intensive blood pressure treatment reduced white matter hyperintensities, which are MRI-visible signs of vascular damage linked to cognitive decline.³ White matter hyperintensities reflect the kind of chronic small vessel injury that accumulates silently over years, so reducing them suggests the damage is being slowed at a structural level rather than merely masked.

The practical takeaway is that blood pressure management matters enormously, but it needs to be calibrated. For someone already living with vascular dementia, the sweet spot is typically moderate control rather than aggressive reduction. This is something to discuss carefully with a doctor, because the optimal target may differ from standard blood pressure guidelines designed for the general population.

Medications That Help With Symptoms

No drug is approved specifically to reverse vascular dementia, but several medications originally developed for Alzheimer’s disease have shown modest benefit in vascular cognitive impairment. A network meta-analysis comparing cholinesterase inhibitors and memantine found that donepezil at 10 mg provided the broadest benefits, improving cognition, executive function, and overall clinical status. Memantine emerged as a strong alternative when balancing effectiveness against side effects.⁴ A clinical trial comparing these drugs head-to-head confirmed that both donepezil and memantine significantly raised cognitive test scores, while galantamine and rivastigmine improved blood flow velocity in certain brain arteries.⁵

These medications do not stop the underlying vascular disease. What they do is boost the brain’s remaining chemical signaling, helping surviving neurons work more efficiently. The improvements tend to be modest on cognitive testing scales, and they don’t work for everyone, but for some patients the difference is meaningful in daily life. Families should know that “modest” on a clinical scale can translate to a noticeable difference in a person’s ability to follow conversations, manage medications, or handle routine tasks.

Preventing the Next Stroke

Because vascular dementia often progresses in a stepwise fashion, with each new stroke or vascular event causing another drop in function, a major part of slowing the disease is simply preventing the next stroke. Antiplatelet medications like aspirin and cilostazol reduce the risk of blood clots forming in brain vessels. Cilostazol also has a vasodilatory effect, meaning it helps open blood vessels, which may provide extra benefit for maintaining blood flow to vulnerable brain areas.⁶

The evidence here is more about prevention than reversal. Each stroke prevented is brain tissue preserved, and over months to years, the cognitive trajectory of someone on appropriate antiplatelet or anticoagulant therapy can look meaningfully different from someone who is not. For patients with atrial fibrillation (an irregular heart rhythm that increases stroke risk), anticoagulation therapy is especially important and is often a cornerstone of the treatment plan.

Diabetes and Other Metabolic Factors

Type 2 diabetes substantially raises the risk of vascular dementia, and the worse the blood sugar control, the higher the risk. A large Swedish registry study found that people with type 2 diabetes had about a 34% higher risk of vascular dementia compared to those without diabetes. Among diabetic patients with the poorest blood sugar control, the risk nearly doubled.⁷ The same study found that diastolic blood pressure was the single strongest risk factor driving vascular dementia risk in diabetic patients, followed by systolic blood pressure and the number of years a person had lived with diabetes.

This matters for slowing vascular dementia because it means that good diabetes management is, in effect, brain protection. Keeping blood sugar in a reasonable range reduces the ongoing damage to small blood vessels throughout the brain. Combined with blood pressure control, this addresses the two biggest metabolic drivers of the disease simultaneously.

Exercise and Brain Blood Flow

Physical activity may be one of the most underused tools for slowing vascular cognitive decline. In an experimental model of vascular cognitive impairment, exercise therapy increased and sustained improved cerebral blood flow and cognitive function, reduced brain cell death, and protected the brain’s white matter from damage.⁸ The benefits were tied to multiple mechanisms: improved deformability of red blood cells (making it easier for them to squeeze through narrowed vessels), activation of enzymes involved in blood vessel health, and direct increases in blood flow.

Translating animal findings to humans requires caution, but the picture from human studies is consistent. Aerobic exercise improves cardiovascular fitness, lowers blood pressure, improves insulin sensitivity, and reduces inflammation, all of which protect brain vasculature. For someone with vascular dementia, even moderate activity like brisk walking several times a week can be meaningful. The challenge is that vascular dementia often brings motor difficulties, balance problems, and fatigue. A supervised exercise program tailored to the person’s abilities is usually the most realistic approach.

Diet and Cognitive Protection

Dietary patterns rich in fruits, leafy green vegetables, fish, nuts, and olive oil, the hallmarks of Mediterranean-style diets, have been linked to slower cognitive decline.⁹ While most of this research has focused on Alzheimer’s disease and general age-related cognitive decline rather than vascular dementia specifically, the overlap makes sense. These dietary patterns reduce blood pressure, improve cholesterol profiles, lower inflammation, and benefit blood vessel health, all of which directly address the vascular pathology that drives vascular dementia.

The earlier JAMA study on multi-infarct dementia found that among patients who did not have high blood pressure, the factor most associated with cognitive improvement was quitting smoking.² Smoking damages blood vessels throughout the body, including the brain, and stopping that damage allows some degree of vascular recovery. Combining smoking cessation with dietary improvements and exercise creates a synergistic effect on vascular health that no single intervention achieves alone.

Sleep Apnea and Its Hidden Role

Obstructive sleep apnea, a condition where breathing repeatedly stops during sleep, is increasingly recognized as a contributor to cognitive decline and vascular brain damage. Each apnea episode causes a brief drop in blood oxygen, and over years, these repeated oxygen drops can accelerate small vessel disease in the brain. Treating sleep apnea with continuous positive airway pressure (CPAP) appears to make a real difference. A retrospective study found that good CPAP adherence for two to twelve months was associated with cognitive test scores roughly two points higher on a standard assessment compared to poor adherence or no CPAP use.¹⁰

Two points on a cognitive scale sounds small, but in the context of dementia, where the trajectory is usually downward, a gain of that magnitude is clinically meaningful. Many people with vascular dementia have undiagnosed sleep apnea, particularly those who are overweight, have high blood pressure, or snore heavily. Screening for it and treating it if present is one of those low-hanging interventions that can make a real difference but often gets overlooked.

Cognitive Rehabilitation

Structured cognitive rehabilitation, programs that systematically exercise memory, attention, and problem-solving, can help people with vascular dementia make better use of their remaining cognitive reserves. Animal research has shown that enriched environments providing mental and physical stimulation significantly reduce learning and memory deficits in models of vascular dementia and even normalize the physical structure of neurons in the hippocampus, a brain region critical for memory.¹¹ These findings point to genuine neuroplasticity, the brain physically remodeling itself in response to stimulation, even after vascular damage has occurred.

Cognitive rehabilitation in stroke patients has also been linked to increases in endogenous growth factors, the brain’s own repair signals.¹² In practical terms, this means that engaging in mentally stimulating activities is not just “keeping busy” but actively promoting the brain’s ability to compensate for lost function. Formal rehabilitation programs run by occupational therapists or neuropsychologists are ideal, but regular engagement with puzzles, social activities, learning new skills, and other cognitively demanding activities contributes to the same underlying process.

The Mixed Dementia Complication

One reason vascular dementia is hard to talk about in clean terms is that most older adults with dementia do not have just one type. Mixed dementia, where Alzheimer’s pathology and vascular pathology coexist in the same brain, is extremely common.¹³ Vascular dysfunction is now understood to predate cognitive decline even in Alzheimer’s disease, and most dementias at older ages involve contributions from both vascular and neurodegenerative processes.¹⁴

This overlap matters for the question of reversibility. The vascular component of mixed dementia is the part most likely to respond to treatment, through blood pressure control, metabolic management, and the other strategies discussed above. The Alzheimer’s component is harder to slow with currently available therapies. So a person with mixed dementia who aggressively manages their vascular risk factors may still see some cognitive benefit, even though the Alzheimer’s pathology continues. Knowing the proportion of vascular versus neurodegenerative contributions in a given patient helps set realistic expectations, and neuroimaging can increasingly help clinicians estimate that proportion.

The blood-brain barrier itself is a site where the two diseases intersect. Damage to the barrier in vascular dementia increases the expression of molecules involved in amyloid accumulation, the hallmark of Alzheimer’s disease.¹⁵ Protecting vascular health may therefore slow not only the vascular dementia itself but also reduce the acceleration of any coexisting Alzheimer’s pathology.

Emerging Approaches

Several newer interventions are under investigation. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that uses magnetic pulses to stimulate specific brain regions, has shown promise when combined with medication. A randomized trial found that rTMS combined with donepezil produced significantly greater cognitive improvements after six weeks than donepezil alone in patients with cognitive impairment from small vessel cerebrovascular disease.¹⁶ Whether those gains persist long term and whether the technique can be scaled beyond clinical trials remains to be seen.

For genetically driven forms of vascular dementia, the research landscape is different. CADASIL, a condition caused by mutations in the NOTCH3 gene, produces strokes and cognitive decline through a mechanism distinct from typical vascular dementia, involving progressive damage to small cerebral blood vessels.¹⁷ There is no approved treatment for CADASIL yet, but researchers are actively exploring disease models and therapeutic approaches.¹⁸ One line of investigation involves edaravone dexborneol, a drug used for acute stroke in China, which has shown the ability to partially reverse CADASIL-like pathology in laboratory cells by restoring a disrupted signaling pathway.¹⁹ This is very early-stage work, but it represents the kind of targeted, mechanism-based therapy that could eventually change outcomes for genetic vascular dementias.

Sex Differences in Vascular Dementia

Men and women experience vascular dementia somewhat differently, though the research here is surprisingly thin. Differences in how the disease presents, progresses, and responds to treatment have historically received little attention.²⁰ What is known is that men tend to develop vascular dementia at higher rates, partly because of higher rates of stroke and cardiovascular disease earlier in life. Women’s risk rises sharply after menopause, likely due to the loss of estrogen’s protective effects on blood vessels. The practical implication is that vascular risk factor management may need to be especially aggressive in postmenopausal women, and clinicians should not assume that a woman’s lower pre-menopausal stroke risk carries over into older age.

The Two Faces of the Disease

Vascular dementia is not one uniform condition. Its two main forms, cortical (multi-infarct) dementia and subcortical small vessel disease, behave quite differently. Subcortical vascular dementia, the more common form, tends to cause slowed thinking, difficulty with planning and organizing, and reduced motor performance rather than the memory loss most people associate with dementia.²¹ Multi-infarct dementia, by contrast, can produce a wider range of symptoms depending on which parts of the brain are affected by strokes, and its progression tends to be more stepwise, with relatively stable periods punctuated by sudden drops after each new vascular event.

This distinction matters for the question of slowing the disease. The stepwise pattern of multi-infarct dementia means that preventing strokes through antiplatelet therapy, blood pressure management, and anticoagulation for atrial fibrillation can create long stable plateaus. The more gradual, progressive course of subcortical small vessel disease requires consistent, long-term management of every contributing factor: blood pressure, blood sugar, cholesterol, smoking, weight, sleep apnea. The strategy is more like managing chronic heart disease than responding to acute events, which makes sustained lifestyle changes especially valuable for this form.